A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Exclusion Criteria

• •Major surgery within four weeks of the start of treatment.
• •Previous other cancer requiring treatment within the previous two years.
• •Clinically significant cardiovascular disease.
• •Any of the following cardiac criteria:
• •Mean resting corrected QT interval (QTc) \> 470 msec obtained from three ECGs and any factors that increase the risk of QTc prolongation or arrhythmic events
• •Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG
• •Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).
• •Gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
• •Subjects being treated with or anticipating the need for treatment with strong CYP3A inhibitors or inducers.